It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus.
Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid Use and Improved Quality of Life in Patients With Chronic Relapsing Pemphigus: BELIEVE Phase II Study (Part A)’ was presented at the AAD VMX, 23-25 April 2021.
- What is the rationale for the use of BTK inhibitors in pemphigus? (0:05)
- What were the aims, design and patient population of the BELIEVE study? (0:51)
- What were the efficacy and quality of life endpoints of the study and how well were these achieved? (2:10)
- What were the safety and tolerability findings of the study? (3:18)
- What future studies are planned? (4:14)
Disclosures: Prof. Dedee Murrell has acted and an investigator and advisor for Principia-Sanofi, ArgenX, Roche-Genentech and Eli Lilly. Prof. Murrell is also the co-inventor of the PDAI and ABQOL measures.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Dermatological Conditions
Sorena Kiani, EAACI 2021: Berotralstat in the Treatment of Hereditary Angioedema
touchIMMUNOLOGY joins Dr Sorena Kiani (Barts Health NHS Trust, London, UK) to discuss the efficacy and safety of berotralstat in the treatment of hereditary angioedema. Questions 1. What are the unmet needs in the treatment of hereditary angioedema (HAE)? (00:17-01:53) 2. What is berotralstat and what is the rationale for its use in HAE? (01:53-03:17) […]
Marcus Maurer, EAACI 2021: Avapritinib for Advanced Systemic Mastocytosis – The PATHFINDER Study
touchIMMUNOLOGY joins Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study. Questions Could you give us a brief overview of the disease burden of advanced systemic mastocytosis and the unmet needs in its treatment? (0:26) […]
Marcus Maurer, EAACI 2021: CDX-0159 for the Treatment of Urticaria
touchIMMUNOLOGY were delighted to talk with Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the Phase 1a study of CDX-0159 in patients with chronic inducible urticaria. Questions What is CDX-0159 and what is the rationale for its use in patients with chronic inducible urticaria? (0:26) Could you tell us […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!